PharmaTelevision - Olivier Litzka of Edmond de Rothschild Investment Partners talks about their funds and focus and why he is optimistic for the future

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Olivier Litzka of Edmond de Rothschild Investment Partners talks about their funds and focus and why he is optimistic for the future

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Olivier Litzka, Partner of Edmond de Rothschild Investment Partners

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Focus and types of funds

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioTrinity 2011. On this show I have Olivier Litzka, who is the Partner at Edmond de Rothschild Investment Partners based in Paris, welcome to the show.

Olivier Litzka:

My pleasure.

Fintan Walton:

Olivier, could you tell us the origins of Edmond de Rothschild Investment Partners and the types of funds that you currently hold and the types of investments you make?

Olivier Litzka:

Okay, the origin is that in year 2000 Edmond de Rothschild Investment Partners was created as a fully owned subsidiary of the bank LCF Rothschild based in Paris. It is focusing on minority investments, gross capital, small caps and life science venture capital, the common denominator of those is that investments are done in minority holdings and therefore a certain interaction with the other shareholders is important. So coming to the life science activity it was created in 2000 a small first fund BioDiscovery-1 in 2000, 26 million very small vehicle, 2004 another one was created 80 million to invest in biotech and medical devices and in 2008 we raised 155 million that is actually the fund BioDiscovery-3 which we use at the moment to invest in companies all over Europe exceptionally also outside of Europe and we're focusing on medical devices and biotechnology companies at different stages, so we are not an early stage investor, we are not a late stage investor we do both, what we are very careful about is that our portfolio is balanced in what we have in this portfolio.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Olivier Litzka

PARTNER

Olivier Litzka has been a partner with Paris-based Edmond de Rothschild Investment Partners (EdRIP) since 2006. He invests primarily in European biotechnology and medtech companies as well as some investments in the United States. In addition to Noxxon Pharma, he serves on the boards of Novexel, Probiodrug, Endosense, SuperSonic Imagine and JenaValve Technologies. Before joining EdRIP, Olivier Litzka spent six years with 3i's life science venture capital practice, based first in Munich and then in Paris. In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting for several years, both in Munich and Paris. Olivier Litzka holds a Ph.D. in molecular microbiology from the Institut f"r Mikrobiologie at the University of Munich and did his scientific research work over several years in Munich and Oxford.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Edmond de Rothschild Investment Partners

Edmond de Rothschild Investment Partners based in Paris is dedicated to minority investments into privately-owned companies. It has currently 800 million Euros under management which is being invested primarily as life sciences venture capital and growth capital. Its Life Sciences Team of six professionals brings together over 30 years of experience in the Life Science industry and more than 50 years of private equity and venture capital experience. The team has approximately 300 million Euros under management after having recently raised 150 million through BioDiscovery 3. Edmond de Rothschild Investment Partners is an independently managed affiliate of La Compagnie Financi"re Edmond de Rothschild Banque.